Rebecca Luse
Director/Board Member at Tourmaline Bio, Inc.
Profile
Ms. Rebecca Luse is Vice President at New Leaf Venture Partners LLC.
She joined New Leaf as an Associate in 2015.
Prior to joining New Leaf, Ms. Luse was a Research Senior Associate for Biotechnology at Jefferies.
She previously was a Research Associate for Specialty Pharmaceuticals at Piper Jaffray, an Analyst at Bay City Capital and a Healthcare Investment Banking Analyst at Banc of America Securities.
Ms. Luse received her undergraduate degree from Indiana University.
Rebecca Luse active positions
| Companies | Position | Start |
|---|---|---|
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Director/Board Member | - |
Deep Track Capital LP
 Deep Track Capital LP Financial ConglomeratesFinance Deep Track Capital LP provides investment advice. The private company is based in Greenwich, CT and has subsidiaries in Cayman Islands. The company was founded in 2020 by David Eric Kroin. David Eric Kroin has been the CEO since 2020. | Private Equity Investor | 2020-12-31 |
Former positions of Rebecca Luse
| Companies | Position | End |
|---|---|---|
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Corporate Officer/Principal | - |
Training of Rebecca Luse
| Indiana University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
Deep Track Capital LP
Deep Track Capital LP Financial ConglomeratesFinance Deep Track Capital LP provides investment advice. The private company is based in Greenwich, CT and has subsidiaries in Cayman Islands. The company was founded in 2020 by David Eric Kroin. David Eric Kroin has been the CEO since 2020. | Finance |
- Stock Market
- Insiders
- Rebecca Luse
